Blog
U.S. Listing | Baide Medical's U.S. IPO Plans NASDAQ Listing, Including Roadshow PPT



Golden Box Group | Listing Guidance | US Listing |IPO |SPAC |RTO | US Listing | Professional US Listing Guidance Institution | US Stock Listing |
Today's Quick Overview of US Listing News!
On January 2, 2024, the China Securities Regulatory Commission issued the filing notice for overseas issuance and listing to Baird Medical Investment Holdings Limited (Baide Medical Investment Co., Ltd.) (hereinafter referred to as: Baide Medical). On December 12, 2023, it submitted Form 425 documents to the U.S. Securities and Exchange Commission (SEC), including the preliminary proxy statement and prospectus. The company completed its listing on the NASDAQ stock exchange in the U.S. through a merger with overseas special purpose acquisition company ExcelFin Acquisition Corp., with the stock ticker BDMD.

Company Profile

According to the prospectus, Baide Medical is a leading Chinese developer and provider of microwave ablation medical devices for minimally invasive tumor treatment. The company focuses on professional fields with significant synergy with microwave ablation technology and huge market growth potential, including benign tumors, especially thyroid nodules and breast nodules; and malignant tumors, especially liver cancer and lung cancer. The company's product supply and pipeline products mainly include microwave ablation therapeutic instruments and microwave ablation needles used in conjunction with the therapeutic instruments.
Baide Medical stated in the prospectus that its revenue mainly comes from the sales of microwave ablation needles. If such products are included in the medical insurance reimbursement list in the future, the product price reduction will have a huge impact on the company's revenue. In addition, the single-product structure will also make the company's performance stability vulnerable to external factors such as policy changes, technological iteration, and market demand. To address this issue, the company plans to continue promoting the research, development and application of microwave ablation technology, expand its product line, develop more indications and product types, and explore overseas markets.
Financial Situation
Financially, in 2019, 2020 and 2021, the company's revenue was RMB 85.029 million, RMB 118 million and RMB 189 million respectively. During the same periods, the total comprehensive income for the year was RMB -49.661 million, RMB 46.692 million and RMB 74.857 million respectively.
It is worth noting that in the first 5 months of 2022, Baide Medical's revenue in the microwave ablation needle sector was RMB 545.2 billion, accounting for as much as 85.5% of total revenue. The gross profit margin of this business was 91.2%, far exceeding Baide Medical's overall gross profit margin. Baide Medical's profitability is entirely supported by a single product pipeline. The single-product structure makes the company's performance stability extremely vulnerable to external factors such as policy changes, technological iteration, and market demand. If such products are included in the medical insurance reimbursement list in the future, product price reductions may have a huge impact on the company's revenue.
Roadshow PPT























Chinese concept stocks' US listings warm up, the record-filing process for overseas issuance and listing of enterprises has accelerated, in2023 year the US stock market has seen strong gains, Chinese enterprises' confidence in listing in the US is also growing. Jinhe Group Xiaojin will share daily hot information on US listings to help enterprises soar in their listings!

Disclaimer: Some information in this article is sourced from the internet. The content published in this article is for sharing purposes only. If there are any content or copyright issues, please contact us and we will handle them as soon as possible.
Originally published on 金盒企业管理集团




